Clinical Trial

A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to assess the safety and tolerability of QLS1209 alone in patients with eligible advanced solid tumors，determine the maximum tolerated dose (MTD) or maximum drug dose（MAD）of QLS1209, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity.
Trial Details
NCT Number NCT06872580
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 149 participants
Start Date 2025-04
Primary Completion 2027-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2025-03-12